咨询客服 咨询客服

From Hypertrophy to Heart Failure: What Is New in Genetic Cardiomyopathies

Abstract:
The purpose of this review is to provide an update on the recent advances in the research and clinical care of patients with the major phenotypes of inherited cardiomyopathies—hypertrophic, dilated, and arrhythmogenic. Developments in genetics, risk stratification, therapies, and disease modeling will be discussed. Diagnostic, prognostic, and therapeutic tools which incorporate genetic and genomic data are being steadily incorporated into the routine clinical care of patients with genetic cardiomyopathies. Human pluripotent stem cells are a breakthrough model system for the study of genetic variation associated with inherited cardiovascular disease. Next-generation sequencing technology and molecular-based diagnostics and therapeutics have emerged as valuable tools to improve the recognition and care of patients with hypertrophic, dilated, and arrhythmogenic cardiomyopathies. Improved adjudication of variant pathogenicity and management of genotype-positive/phenotype-negative individuals are imminent challenges in this realm of precision medicine.
Author Listing: Nosheen Reza;Kiran Musunuru;Anjali Tiku Owens
Volume: 16
Pages: 157 - 167
DOI: 10.1007/s11897-019-00435-0
Language: English
Journal: Current Heart Failure Reports

Current Heart Failure Reports

影响因子:3.8
是否综述期刊:否
是否OA:否
是否预警:不在预警名单内
发行时间:-
ISSN:1546-9530
发刊频率:6 issues per year
收录数据库:Scopus收录
出版国家/地区:-
出版社:Springer Nature

期刊介绍

This journal intends to provide clear, insightful, balanced contributions by international experts that review the most important, recently published clinical findings related to the diagnosis, treatment, management, and prevention of heart failure. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as investigative, pharmacologic, and nonpharmacologic therapies, pathophysiology, and prevention. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.

本杂志旨在提供国际专家的清晰、有见地、平衡的贡献,这些专家回顾了最近发表的与心力衰竭的诊断、治疗、管理和预防相关的最重要的临床发现。我们通过任命国际权威机构担任关键主题领域的章节编辑来实现这一目标,例如研究、药理学和非药理学治疗、病理生理学和预防。而版块编辑则会选择一些主题,让顶尖专家为这些主题撰写全面的评论文章,这些文章强调新的发展和最近发表的重要论文,并通过注释参考文献列表突出显示。一个国际编辑委员会审查年度目录,建议他们国家/地区特别感兴趣的文章,并确保主题是最新的,包括新兴的研究。还提供了该领域知名人士的评论。

年发文量 55
国人发稿量 1
国人发文占比 1.82%
自引率 2.6%
平均录取率 -
平均审稿周期 -
版面费 -
偏重研究方向 Medicine-Emergency Medicine
期刊官网 https://www.springer.com/11897/?utm_medium=display&utm_source=letpub&utm_content=text_link&utm_term=null&utm_campaign=MLSR_11897_AWA1_CN_CNPL_letpb_mp
投稿链接 https://www.editorialmanager.com/chfr/default.aspx

质量指标占比

研究类文章占比 OA被引用占比 撤稿占比 出版后修正文章占比
78.57% 39.55% - -

相关指数

影响因子
影响因子
年发文量
自引率
Cite Score

预警情况

时间 预警情况
2024年02月发布的2024版 不在预警名单中
2023年01月发布的2023版 不在预警名单中
2021年12月发布的2021版 不在预警名单中
2020年12月发布的2020版 不在预警名单中

JCR分区 WOS分区等级:Q1区

版本 按学科 分区
WOS期刊SCI分区
(2021-2022年最新版)
CARDIAC & CARDIOVASCULAR SYSTEMS Q1

中科院分区

版本 大类学科 小类学科 Top期刊 综述期刊
暂无数据